ETNB
ETNB
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $115.824M ▲ | $-111.504M ▼ | 0% | $-0.71 ▼ | $-115.824M ▼ |
| Q1-2025 | $0 ▼ | $75.909M ▼ | $-71.275M ▲ | 0% ▲ | $-0.49 ▲ | $-75.909M ▲ |
| Q4-2024 | $21K ▲ | $121.996M ▼ | $-118.354M ▲ | -563.59K% ▼ | $-1.02 ▲ | $-116.897M ▲ |
| Q3-2024 | $0 | $151.938M ▲ | $-149.073M ▼ | 0% | $-1.39 ▼ | $-146.499M ▼ |
| Q2-2024 | $0 | $53.424M | $-47.971M | 0% | $-0.48 | $-46.951M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $561.164M ▼ | $603.485M ▼ | $81.752M ▲ | $521.733M ▼ |
| Q1-2025 | $638.78M ▲ | $685.031M ▲ | $79.573M ▲ | $605.458M ▲ |
| Q4-2024 | $439.955M ▲ | $478.685M ▲ | $77.896M ▼ | $400.789M ▲ |
| Q3-2024 | $423.774M ▼ | $458.297M ▼ | $80.195M ▲ | $378.102M ▼ |
| Q2-2024 | $531.384M | $582.138M | $67.221M | $514.917M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-111.504M ▼ | $-100.425M ▼ | $-106.622M ▼ | $20.727M ▼ | $-186.32M ▼ | $-100.425M ▼ |
| Q1-2025 | $-71.275M ▲ | $-71.737M ▲ | $-7.833M ▼ | $268.906M ▲ | $189.336M ▲ | $-71.809M ▲ |
| Q4-2024 | $-118.354M ▲ | $-121.58M ▲ | $19.824M ▲ | $136.405M ▲ | $34.649M ▲ | $-121.595M ▲ |
| Q3-2024 | $-149.073M ▼ | $-145.359M ▼ | $-8.639M ▼ | $33.191M ▲ | $-120.807M ▼ | $-145.359M ▼ |
| Q2-2024 | $-47.971M | $-61.164M | $27.849M | $27.96M | $-5.355M | $-61.164M |
About 89bio, Inc.
https://www.89bio.com89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $115.824M ▲ | $-111.504M ▼ | 0% | $-0.71 ▼ | $-115.824M ▼ |
| Q1-2025 | $0 ▼ | $75.909M ▼ | $-71.275M ▲ | 0% ▲ | $-0.49 ▲ | $-75.909M ▲ |
| Q4-2024 | $21K ▲ | $121.996M ▼ | $-118.354M ▲ | -563.59K% ▼ | $-1.02 ▲ | $-116.897M ▲ |
| Q3-2024 | $0 | $151.938M ▲ | $-149.073M ▼ | 0% | $-1.39 ▼ | $-146.499M ▼ |
| Q2-2024 | $0 | $53.424M | $-47.971M | 0% | $-0.48 | $-46.951M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $561.164M ▼ | $603.485M ▼ | $81.752M ▲ | $521.733M ▼ |
| Q1-2025 | $638.78M ▲ | $685.031M ▲ | $79.573M ▲ | $605.458M ▲ |
| Q4-2024 | $439.955M ▲ | $478.685M ▲ | $77.896M ▼ | $400.789M ▲ |
| Q3-2024 | $423.774M ▼ | $458.297M ▼ | $80.195M ▲ | $378.102M ▼ |
| Q2-2024 | $531.384M | $582.138M | $67.221M | $514.917M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-111.504M ▼ | $-100.425M ▼ | $-106.622M ▼ | $20.727M ▼ | $-186.32M ▼ | $-100.425M ▼ |
| Q1-2025 | $-71.275M ▲ | $-71.737M ▲ | $-7.833M ▼ | $268.906M ▲ | $189.336M ▲ | $-71.809M ▲ |
| Q4-2024 | $-118.354M ▲ | $-121.58M ▲ | $19.824M ▲ | $136.405M ▲ | $34.649M ▲ | $-121.595M ▲ |
| Q3-2024 | $-149.073M ▼ | $-145.359M ▼ | $-8.639M ▼ | $33.191M ▲ | $-120.807M ▼ | $-145.359M ▼ |
| Q2-2024 | $-47.971M | $-61.164M | $27.849M | $27.96M | $-5.355M | $-61.164M |
CEO
Rohan Palekar
Compensation Summary
(Year 2024)
CEO
Rohan Palekar
Compensation Summary
(Year 2024)
Most Recent Analyst Grades
B of A Securities
Buy
UBS
Buy
Cantor Fitzgerald
Overweight
Raymond James
Market Perform
RBC Capital
Sector Perform
Wolfe Research
Peer Perform
HC Wainwright & Co.
Neutral
Grade Summary
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
19.89M Shares
$295.163M
PENTWATER CAPITAL MANAGEMENT LP
11.75M Shares
$174.37M
BLACKROCK, INC.
10.316M Shares
$153.095M
DEEP TRACK CAPITAL, LP
9.356M Shares
$138.846M
ADAGE CAPITAL PARTNERS GP, L.L.C.
9.098M Shares
$135.008M
SUVRETTA CAPITAL MANAGEMENT, LLC
8.28M Shares
$122.875M
VANGUARD GROUP INC
8.053M Shares
$119.513M
BLACKROCK INC.
7.016M Shares
$104.111M
AVORO CAPITAL ADVISORS LLC
6.388M Shares
$94.795M
GLAZER CAPITAL, LLC
5.637M Shares
$83.652M
JANUS HENDERSON GROUP PLC
5.378M Shares
$79.812M
STATE STREET CORP
5.286M Shares
$78.449M
PICTET ASSET MANAGEMENT HOLDING SA
4.035M Shares
$59.885M
PICTET ASSET MANAGEMENT SA
3.575M Shares
$53.055M
DEUTSCHE BANK AG\
3.5M Shares
$51.934M
WESTFIELD CAPITAL MANAGEMENT CO LP
3.291M Shares
$48.844M
GEODE CAPITAL MANAGEMENT, LLC
3.092M Shares
$45.89M
SYQUANT CAPITAL SAS
2.594M Shares
$38.49M
KRYGER CAPITAL LTD
2.35M Shares
$34.874M
TIG ADVISORS, LLC
2.187M Shares
$32.45M
Summary
Only Showing The Top 20